<DOC>
	<DOC>NCT00620815</DOC>
	<brief_summary>Evaluate the immune response and reactogenicity of H5N1 vaccination in adults aged 18 years and above (as part of a tetravalent vaccine)</brief_summary>
	<brief_title>Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<criteria>Healthy subjects (aged 18 years and above) who have signed an informed consent form Any acute or chronic illness Receipt of seasonal influenza vaccine for the current season 2007/2008 Known or suspected impairment/alteration of immune function Receipt of another vaccine within 3 weeks prior to Visit 1 or planned vaccination within 3 weeks following the last study vaccination Any serious disease Hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein,neomycin or kanamycin or any other component of the study vaccine Receipt of blood, blood products or immunoglobulins 3 months prior to vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>avian flu</keyword>
	<keyword>seasonal influenza vaccine</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>prepandemic vaccine</keyword>
	<keyword>virus strain with the potential to cause pandemic</keyword>
	<keyword>tetravalent vaccine</keyword>
	<keyword>Prophylaxis of influenza</keyword>
</DOC>